Meeting
2016 Gastrointestinal Cancers Symposium
Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials.
Authors
Sarah Chrabaszcz
Medical College of WIsconsin, Milwaukee, WI
Sarah Chrabaszcz , Rahul Rajeev , Brittany Klooster , Ashley Chinn , T. Clark Gamblin , Fabian McCartney Johnston , Ben George , Anjishnu Banerjee , Kiran Turaga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 641)
DOI
10.1200/jco.2016.34.4_suppl.641
Abstract #
641
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
First Author: S.P. Somashekhar
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
First Author: Christopher Williams
Poster
2018 ASCO Annual Meeting
Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
First Author: Shukui Qin
Poster
2017 Gastrointestinal Cancers Symposium
CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
First Author: Yu Sunakawa